Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Other Non-Current Assets came in at $10.8 million in Q2 2026, up 32.2% YoY from $8.2 million in Q2 2025, and down 2.94% on a QoQ basis from $11.2 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Other Non-Current Assets data on file, last reported at $10.8 million in Q2 2026.
- Quarterly Other Non-Current Assets rose 32.2% year-over-year to $10.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.8 million (up 32.2% YoY) and the FY2025 annual result came in at $11.3 million, up 9.62% from the prior year.
- Other Non-Current Assets slipped to $10.8 million in Q2 2026, from $11.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $11.3 million in Q4 2025 to a low of $827000.0 in Q4 2023.
- A 5-year average of $6.6 million and a median of $6.9 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets sank 85.8% — and 2024, when it soared 1147.28%.
- Tracing KNSA's Other Non-Current Assets over 5 years: stood at $5.8 million in 2022, then slumped by 85.8% to $827000.0 in 2023, then soared by 1147.28% to $10.3 million in 2024, then grew by 9.62% to $11.3 million in 2025, then decreased by 4.18% to $10.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $10.8 million (Q2 2026), $11.2 million (Q1 2026), and $11.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 13.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.08 Bn | 5.56 Bn | 220.03 Mn | 10.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.83 Mn |
| Mar 31, 2026 | 11.16 Mn |
| Dec 31, 2025 | 11.31 Mn |
| Sep 30, 2025 | 8.29 Mn |
| Jun 30, 2025 | 8.20 Mn |
| Mar 31, 2025 | 8.20 Mn |
| Dec 31, 2024 | 10.32 Mn |
| Sep 30, 2024 | 7.85 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 4.13 Mn |
| Dec 31, 2023 | 827,000.00 |
| Sep 30, 2023 | 2.29 Mn |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 2.32 Mn |
| Dec 31, 2022 | 5.82 Mn |
| Sep 30, 2022 | 5.63 Mn |
| Jun 30, 2022 | 5.67 Mn |
| Mar 31, 2022 | 5.92 Mn |
| Dec 31, 2021 | 8.72 Mn |
| Sep 30, 2021 | 6.55 Mn |